Alnylam Pharmace. buy Saftman
Start price
08.07.21
/
50%
€146.45
Target price
08.07.22
-
Performance (%)
2.31%
End price
08.07.22
€149.84
Summary
This prediction ended on 08.07.22 with a price of €149.84. With a performance of 2.31%, the BUY prediction by Saftman for Alnylam Pharmace. closed with a slight gain. Saftman has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Alnylam Pharmace. | -2.434% | -2.434% | 15.477% | 50.645% |
| iShares Core DAX® | -2,12 % | -8,18 % | -1,47 % | 54,14 % |
| iShares Nasdaq 100 | -1,13 % | 0,91 % | 19,96 % | 83,32 % |
| iShares Nikkei 225® | -0,66 % | -6,26 % | 27,47 % | 53,61 % |
| iShares S&P 500 | -1,26 % | -1,00 % | 13,63 % | 62,62 % |
Comments by Saftman for this prediction
In the thread Alnylam Pharmace. diskutieren
Saftman hat das Wertpapier Alnylam Pharmace. in seinem Wikifolio Langfristige Aufwärtstrends gekauft.
In the thread Trading Alnylam Pharmace.
Die von Saftman gewählte maximale Laufzeit wurde überschritten